A Phase Ib Open-label Clinical Trial of Once Daily Oral Treatment of Afatinib Plus Weekly Intravenous Infusion of Xentuzumab (BI 836845) in Patients With EGFR Mutant Non-small Cell Lung Cancer With Progression Following Prior EGFR Tyrosine Kinase Inhibitor
Phase of Trial: Phase I
Latest Information Update: 03 May 2018
Price : $35 *
At a glance
- Drugs Xentuzumab (Primary) ; Afatinib
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Boehringer Ingelheim
- 30 Apr 2018 Status changed from active, no longer recruiting to completed.
- 29 Mar 2018 Planned End Date changed from 2 Mar 2018 to 26 Apr 2018.
- 29 Mar 2018 Planned primary completion date changed from 2 Mar 2018 to 26 Apr 2018.